Skip to main content

Amersham Licenses Tagging and Imaging Systems to Lilly

NEW YORK, Nov. 7 (GenomeWeb News) - Amersham announced today that Eli Lilly has licensed the rights to Amersham's Aequorea Victoria Green Fluorescent Protein and has secured rights to operate under Biolmage's Redistribution patent portfolio for monitoring intracellular signaling pathways.


Lilly will use the licensed technologies, along with a recently purchased IN Cell Analyzer 3000 high-throughput imaging system from Amersham, to look at drug targets in a biological context, the companies said.


Financial details of the agreement were not disclosed.


The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.